A health worker organises samples collected for further testing at Thanon Mitr Market, amid the spread of the coronavirus disease , in Bangkok, Thailand, January 19, 2021. REUTERS/Chalinee Thirasupa
He said that royally-owned Siam Bioscience had been the most obvious choice of many companies considered for technology transfer from pharmaceutical firm AstraZeneca to make 200 million vaccine doses each year for Thailand and other nations. Thanathorn made his comments on Facebook Live on Monday at an event titled “Royal Vaccine: Who Benefits and Who Doesn’t?”
Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più: